McFarland HF - Search Results

1

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis.

Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R. Zipp F, et al. Among authors: mcfarland hf. Ann Neurol. 1998 Jan;43(1):116-20. doi: 10.1002/ana.410430120. Ann Neurol. 1998. PMID: 9450777

2

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history.

Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Harris JO, et al. Among authors: mcfarland hf. Ann Neurol. 1991 May;29(5):548-55. doi: 10.1002/ana.410290515. Ann Neurol. 1991. PMID: 1859184

3

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.

Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF. Stone LA, et al. Among authors: mcfarland hf. Ann Neurol. 1995 May;37(5):611-9. doi: 10.1002/ana.410370511. Ann Neurol. 1995. PMID: 7755356 Clinical Trial.

4

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.

Stone LA, Smith ME, Albert PS, Bash CN, Maloni H, Frank JA, McFarland HF. Stone LA, et al. Among authors: mcfarland hf. Neurology. 1995 Jun;45(6):1122-6. doi: 10.1212/wnl.45.6.1122. Neurology. 1995. PMID: 7783875

5

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.

Calabresi PA, Stone LA, Bash CN, Frank JA, McFarland HF. Calabresi PA, et al. Among authors: mcfarland hf. Neurology. 1997 May;48(5):1446-8. doi: 10.1212/wnl.48.5.1446. Neurology. 1997. PMID: 9153489

6

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF. Calabresi PA, et al. Among authors: mcfarland hf. Ann Neurol. 1997 May;41(5):669-74. doi: 10.1002/ana.410410517. Ann Neurol. 1997. PMID: 9153530 Clinical Trial.

7

Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.

Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H, McFarland HF. Stone LA, et al. Among authors: mcfarland hf. Neurology. 1997 Sep;49(3):862-9. doi: 10.1212/wnl.49.3.862. Neurology. 1997. PMID: 9305355

8

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF. Frank JA, et al. Among authors: mcfarland hf. Neurology. 2004 Mar 9;62(5):719-25. doi: 10.1212/01.wnl.0000113765.75855.19. Neurology. 2004. PMID: 15007120 Clinical Trial.

9

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.

McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, Patronas N, Maloni H, McFarlin DE. McFarland HF, et al. Ann Neurol. 1992 Dec;32(6):758-66. doi: 10.1002/ana.410320609. Ann Neurol. 1992. PMID: 1471866

10

Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis.

Stone LA, Albert PS, Smith ME, DeCarli C, Armstrong MR, McFarlin DE, Frank JA, McFarland HF. Stone LA, et al. Among authors: mcfarland hf. Neurology. 1995 Oct;45(10):1808-14. doi: 10.1212/wnl.45.10.1808. Neurology. 1995. PMID: 7477973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

272 results

Search Page

Filters